Investor Relations header Spectrum Pharmaceuticals Investor Relations picture
      
Oncology, Generics, Neurology Drugs About Spectrum Pharmaceuticals SPPI Investor Relations SPPI News
shadow area

Events & Presentations

Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trial

Feb 4, 2010 at 1:00 PM ET

Registration is required to listen to this webcast.

* Fields Are Required





** An email will be sent to your email address confirming your identity. You will then be given options to sign up for webcast and other alerts.

Stock Information
NASDAQ:SPPI
$3.90   + 0.10
Sep 9, 2010
1:09 PM ET
Quotes delayed at least 20 minutes.
Information provided by eSignal.
Shareholder Tools

Search Investor Relations



 All contents © Copyright Spectrum Pharmaceuticals, Inc. 2010. All Rights Reserved.  Terms of Use